The emergence of GLP-1 receptor agonists (semaglutide, tirzepatide) as mainstream weight management medications is reshaping demand patterns across the entire health and nutrition ingredients industry. As users of these medications experience reduced appetite and altered gut motility, the role of dietary fibre in supporting their nutritional needs has come into sharp focus.
Why Fibre Demand Is Surging
GLP-1 users consume significantly less food volume, making nutrient density and gut health support critical. Prebiotic fibres — particularly soluble fibres like acacia gum — are increasingly recommended by healthcare practitioners working with GLP-1 patients to support microbiome health, satiety signalling, and bowel regularity.
The Acacia Gum Opportunity
Acacia gum's unique combination of high prebiotic potency, complete flavour neutrality, and exceptional solubility makes it the ideal fibre ingredient for GLP-1 companion products. It can be incorporated at meaningful doses (10–15g/serving) without affecting texture or taste — a critical advantage when targeting users with heightened food sensitivities.
At BioSource Trading, we have seen a significant increase in acacia gum enquiries from supplement brands, RTD beverage companies, and functional food manufacturers over the past 12 months — directly correlated with the GLP-1 market expansion.
